The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist

International Journal of Women's Health

Volumn 3, Issue 1, 2011, Pages 243-255

  Seyhan, Ayse ^a   Ata, Baris ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Assisted reproduction; Controlled ovarian hyperstimulation; Follicle stimulating hormone; In vitro fertilization; Long acting

Indexed keywords

CHORIONIC GONADOTROPIN; CORIFOLLITROPIN ALFA; FOLLITROPIN; GLYCOPROTEIN; GONADORELIN ANTAGONIST; INHIBIN B; LUTEINIZING HORMONE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT FOLLITROPIN; THYROTROPIN;

ANTEPARTUM HEMORRHAGE; AREA UNDER THE CURVE; BETA CHAIN; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HYPERSENSITIVITY; EMBRYOLOGY; FEMALE; FERTILIZATION IN VITRO; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE REACTION; LUTEINIZING HORMONE BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MULTIPLE PREGNANCY; NONHUMAN; OOCYTE; OVARIAN STIMULATION; OVARY HYPERSTIMULATION; PELVIS PAIN SYNDROME; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREGNANCY RATE; REVIEW; SINGLE DRUG DOSE; STIMULATION; THYROTROPIN BLOOD LEVEL;

EID: 84055216917     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Collins J. An international survey of the health economics of IVF and ICSI. Hum Reprod Update. 2002;8(3):265-277.
2. Mosher W, Pratt W. Fecundity and infertility in the United States, 1965-1988. Advance Data from Vital and Health Statistics, No. 192. Hyattsville, MD: National Center for Health Statistics; 1990.
3. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 1992;58(5):888-896.
4. Tan SL, Maconochie N, Doyle P, et al. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin. Am J Obstet Gynecol. 1994;171(2):513-520.
5. Tan SL, Royston P, Campbell S, et al. Cumulative conception and livebirth rates after in-vitro fertilisation. Lancet. 1992;339(8806):1390-1394.
6. Domar AD, Zuttermeister PC, Friedman R. The psychological impact of infertility: a comparison with patients with other medical conditions. J Psychosom Obstet Gynaecol. 1993;(Suppl 14):45-52.
7. Olivius C, Friden B, Borg G, Bergh C. Why do couples discontinue in vitro fertilization treatment? A cohort study. Fertil Steril. 2004;81(2):258-261.
8. Verberg MF, Eijkemans MJ, Heijnen EM, et al. Why do couples dropout from IVF treatment? A prospective cohort study. Hum Reprod. 2008;23(9):2050-2055.
9. Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;(5):CD001750.
10. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online. 2006;13(5):628-638.
11. Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Human Reprod. 2002;17(8):1987-1993.
12. Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metabol. 2004;89(5):2062-2070.
13. The Corifollitropin Alfa Dose-fnding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reprod. 2008;23(11):2484-2492.
14. Devroey P, Boostanfar R, Koper N P, Mannaerts BM, Ijzerman-Boon PC, Fauser BC. A double-blind, non-inferiority RCT comparing corifol-litropin alfa and recombinant FSH during the frst seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reprod. 2009;24(12):3063-3072.
15. The Corifollitropin Alfa Ensure study group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online. 2010;21(1):66-76.
16. Amin HK, Hunter WM. Human pituitary follicle-stimulating hormone: distribution, plasma clearance and urinary excretion as determined by radioimmunoassay. J Endocrinol. 1970;48(3):307-317.
17. Ryan RJ, Charlesworth MC, McCormick DJ, Milius R P, Keutmann HT. The glycoprotein hormones: recent studies of structure-function relationships. FASEB J. 1988;2(11):2661-2669.
18. Sowers JR, Pekary AE, Hershman JM, Kanter M, DiStefano JJ. Metabolism of exogenous human chorionic gonadotrophin in men. J Endocrinol. 1979;80(1):83-89.
19. Rizkallah T, Gurpide E, Vande Wiele RL. Metabolism of HCG in man. J Clin Endocrinol Metab. 1969;29(1):92-100.
20. Kohler PO, Ross GT, Odell WD. Metabolic clearance and production rates of human luteinizing hormone in pre- and postmenopausal women. J Clin Invest. 1968;47(1):38-47.
21. Kessler MJ, Mise T, Ghai RD, Bahl OP. Structure and location of the O-glycosidic carbohydrate units of human chorionic gonadotropin. J Biol Chem. 1979;254(16):7909-7914.
22. Matzuk MM, Hsueh AJ, Lapolt P, Tsafriri A, Keene JL, Boime I. The biological role of the carboxyl-terminal extension of human chorionic gonadotropin [corrected] beta-subunit. Endocrinology. 1990;126(1):376-383.
23. Creus S, Chaia Z, Pellizzari EH, Cigorraga SB, Ulloa-Aguirre A, Campo S. Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity. Mol Cell Endocrinol. 2001;174(1-2):41-49.
24. D'Antonio M, Borrelli F, Datola A, et al. Biological characterization of recombinant human follicle stimulating hormone isoforms. Hum Reprod. 1999;14(5):1160-1167.
25. Miller C, Ulloa-Aguirre A, Hyland L, Chappel S. Pituitary follicle-stimulating hormone heterogeneity: assessment of biologic activities of each follicle-stimulating hormone form. Fertil Steril. 1983;40(2):242-247.
26. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Human Reprod Update. 2009;15(3):309-321.
27. Weenen C, Pena JE, Pollak SV, et al. Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. J Clin Endocrinol Metab. 2004;89(10):5204-5212.
28. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A. 1992;89(10):4304-4308.
29. LaPolt PS, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJ. Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. Endocrinology. 1992;131(6):2514-2520.
30. Verbost P, Sloot WN, Rose UM, de Leeuw R, Hanssen RG, Verheijden GF. Pharmacologic profiling of corifollitropin alfa, the frst developed sustained follicle stimulant. Eur J Pharmacol. 2011;651(1-3):227-233.
31. Steelman SL, Pohley FM. Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin. Endocrinology. 1953;53(6):604-616.
32. Bouloux PM, Handelsman DJ, Jockenhovel F, et al. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Human Reprod. 2001;16(8):1592-1597.
33. 8) by Pen-injector and syringe. Hum Reprod. 1999;14(7):1698-1702.
34. Mannaerts BM, Rombout F, Out HJ, Coelingh Bennink H. Clinical profling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and effcacy. Hum Reprod Update. 1996;2(2):153-161.
35. Voortman G, Mannaerts BM, Huisman JA. A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim*/Puregon) in healthy female volunteers. Fertil Steril. 2000;73(6):1187-1193.
36. le Cotonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil Steril. 1994;61(4):679-686.
37. Balen AH, Mulders AG, Fauser BC, et al. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J Clin Endocrinol Metab. 2004;89(12):6297-6304.
38. Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM. Pharmacokinetics and follicular dynamics of corifol-litropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online. 2010;21(5):593-601.
39. Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, cori-follitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2004;89(5):2062-2070.
40. Beckers NG, Macklon NS, Devroey P, Platteau P, Boerrigter PJ, Fauser BC. First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertil Steril. 2003;79(3):621-623.
41. Norman RJ, Zegers-Hochschild F, Salle BS, et al. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod. 2011;26(8): 2200-2208.
42. de Greef R, Zandvliet AS, de Haan AF, Ijzerman-Boon PC, Marintche-va-Petrova M, Mannaerts BM. Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clin Pharmacol Ther. 2010;88(1):79-87.
43. Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15(7): 1490-1498.
44. Fluker M, Grifo J, Leader A, et al. Effcacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75(1):38-45.